Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Phase II trial suggests radiation could ward off complications of bone lesions and extend overall survival for patients with advanced cancers
News | Radiation Therapy
Radiation Therapy for High-risk, Asymptomatic Bone Metastases May Prevent Pain and Prolong Life

October 23, 2022 — Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and ...

Time October 23, 2022
arrow
Phase III study provides randomized evidence of equivalent outcomes and side effects with 5 vs. 8 weeks of radiation for high-risk disease
News | Prostate Cancer
Shortened Course of Radiation Therapy Safe and Effective for Men with High-risk Prostate Cancer

October 23, 2022 — A new randomized study confirms that men with high-risk prostate cancer can be treated with five ...

Time October 23, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

September 28, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 28, 2022
arrow
Precision cancer medicine is the goal of a new multidisciplinary team examining radiation therapy combined with immunotherapy
News | Prostate Cancer
Sylvester Game Changer Vehicle Among First in Nation to Offer Mobile Prostate Cancer Screening

September 26, 2022 — Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game ...

Time September 26, 2022
arrow
Hoag Memorial Hospital Presbyterian has been named a Radiopharmaceutical Therapy Center of Excellence (RTCoE) by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a distinction held by only 17 centers in the U.S.
News | Radiology Business
Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials

September 8, 2022 — Hoag Memorial Hospital Presbyterian has been named a Radiopharmaceutical Therapy Center of ...

Time September 08, 2022
arrow
Patients with detectable PSA (0.2-2.0 ng/mL) post-prostatectomy considered for salvage radiotherapy undergoing 18F-DCFPyl PSMA PET/CT staging. Image created by M.Ng et al, GenesisCare, Melbourne, Australia.
News | Prostate Cancer
New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50% of Prostate Cancer Patients

September 8, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with ...

Time September 08, 2022
arrow
A new study published by University of Kentucky Markey Cancer Center researchers suggests that the common steroid betamethasone could be used to reduce unwanted side effects of radiation treatments for prostate cancer.
News | Prostate Cancer
Betamethasone Could Improve Outcomes for Prostate Cancer Radiation Therapy

August 16, 2022 — A new study published by University of Kentucky Markey Cancer Center researchers suggests that the ...

Time August 16, 2022
arrow
Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to significantly improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx).
News | Prostate Cancer
Bot Image Receives FDA Clearance for Artificial Intelligence Software Used in Detection and Diagnosis of Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
arrow
NorthStar will provide Clovis with its environmentally preferred, high purity non-carrier-added (n.c.a.) Ac-225
News | PET Imaging
Independent Clinical Studies Published Regarding Performance of Axumin (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
arrow
News | Prostate Cancer
Insightec Receives FDA IDE Approval for Prostate Cancer Comparative Study Using High Intensity Focused Ultrasound Technology

July 1, 2022 — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care ...

Time July 01, 2022
arrow
Heat maps of PSMA PET prostatic fossa recurrence in patients with recurrence limited to the prostate fossa (miTr N0 M0, n=127), pelvic nodal disease (miTr N1 M0, n=30), distant organs/extra-pelvic nodal disease (miTr N0 M1, n=32) and pelvic nodal plus distant organs/extra-pelvic nodal disease (miTr N1 M1, n=37). The yellow contour represents the RTOG CTV
News | Prostate Cancer
PSMA PET Highlights Need for Updated Prostate Cancer Therapy Guidelines

June 15, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of ...

Time June 15, 2022
arrow
At the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2022 Annual Meeting, GE Healthcare showcases cutting-edge solutions spanning the care continuum and enabling theranostics in prostate cancer
News | Prostate Cancer
GE Healthcare’s Total Molecular Imaging Solutions Enable Precision Health and Theranostics for Personalized Prostate Cancer Care

June 10, 2022 — GE Healthcare provides cutting-edge molecular imaging solutions that enable and increase access to ...

Time June 10, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

June 8, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 08, 2022
arrow
Craig Rogers, M.D., performed a robotic high intensity ultrasound case for Charles Rashid, 64, on April 8, 2022. Image courtesy of Henry Ford Health
News | Focused Ultrasound Therapy
Henry Ford Health First in Michigan to Offer Robotic High-intensity Focused Ultrasound for Prostate Cancer

May 12, 2022 — Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for ...

Time May 12, 2022
arrow
Lumea, a global leader in integrated digital pathology solutions and Verily, an Alphabet precision health company, announced a strategic development partnership.
News | Digital Pathology
Verily and Lumea Announce Development Partnership

April 27, 2022 — Lumea, a global leader in integrated digital pathology solutions and Verily, an Alphabet precision ...

Time April 27, 2022
arrow
Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer.
News | Prostate Cancer
Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases

April 25, 2022 — Over the past 15 years, public health authorities have downgraded recommendations for the prostate ...

Time April 25, 2022
arrow
Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug Application (IND) application for 177Lu-rhPSMA-10.1.
News | Prostate Cancer
Blue Earth Therapeutics Announces U.S. FDA Clearance for Investigational New Drug (IND) Application for 177Lu-rhPSMA-10.1

April 19, 2022 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time April 19, 2022
arrow
Prof. Dr. Samer Ezziddin, image courtesy of Thorsten Mohr/Saarland University
News | Prostate Cancer
New Radiotracer Yields Huge Increase in Accuracy of Localizing Prostate Cancer relapses

April 15, 2022 — Prostate cancer is the most common malignant tumor in men in Germany, with about 62,000 new cases ...

Time April 14, 2022
arrow
Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.
News | PET-CT
New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

Time April 11, 2022
arrow
RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced artificial intelligence (AI) and computer vision solutions, announced a new tool for prostate MRI analysis.
News | Prostate Cancer
New AI Tool for Prostate MRI Analysis to Support PI-RADS Scoring

April 11, 2022 — RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced ...

Time April 11, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now